330 filings
Page 11 of 17
6-K
d11td ckd
15 May 17
Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
12:00am
6-K
rtujhecenp
15 May 17
Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors
12:00am
6-K
hudghjimomt
15 May 17
Interim Condensed Consolidated Financial Statements
12:00am
6-K
ytw730ludm7cy1wg77
4 May 17
Aurinia to Present at Bloom Burton & Co. Healthcare Conference
12:00am
6-K
aldff u363l4sgvo70
20 Apr 17
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
tnx nz3u1ubp7txhorbs
20 Apr 17
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
nc36htt339jgi0vfklfw
17 Apr 17
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
ff506elvo3z9li7afp1
6 Apr 17
Aurinia Announces Development Plans for Voclosporin in Europe and Japan
12:00am
6-K
6ist71
27 Mar 17
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
8jpxn
23 Mar 17
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
xomgdkly rg
20 Mar 17
Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
12:00am
6-K
jx8ho2lo
16 Mar 17
As Representatives of the Several Underwriters
12:00am
6-K
7m6o b0pdjrpjlz
16 Mar 17
Aurinia Pharmaceuticals Inc. 6-K
12:00am
6-K
nc5tpboj 04z15
14 Mar 17
Aurinia Prices US$150.5 Million Public Offering of Common Shares
12:00am
FWP
gpou0r5pnen
14 Mar 17
Free writing prospectus
12:00am
SUPPL
hdcmum54
14 Mar 17
Supplemental materials (foreign)
12:00am
SUPPL
yescj8e8ukh47eod su
13 Mar 17
Supplemental materials (foreign)
12:00am
6-K
wm6j47q u7i
13 Mar 17
Aurinia Announces Public Offering of Common Shares
12:00am
40-F
b1y4p7p6nby6lbgy 7l
9 Mar 17
Annual report (Canada)
12:00am
6-K
nqx jfp91
9 Mar 17
Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights
12:00am